Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Australian Clinical Labs Ltd ( (AU:ACL) ) has shared an update.
Macquarie Group Limited and its controlled entities have lodged a notice indicating they have ceased to be a substantial shareholder in Australian Clinical Labs Ltd. The change in substantial holding, formalised on 8 April 2026, signals a withdrawal or significant reduction of Macquarie’s equity position, which may affect the company’s shareholder base composition and could influence perceptions of institutional support for the pathology operator.
The notice also records changes in associations among Macquarie Group’s related entities in relation to voting interests in Australian Clinical Labs. While no specific transaction details are disclosed in this extract, the move marks a reshaping of major ownership interests and may prompt closer investor scrutiny of liquidity, governance dynamics, and potential future shifts in the company’s register.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd is an Australian pathology services provider, operating medical laboratories that conduct diagnostic tests for healthcare providers and patients. The company focuses on clinical pathology and related diagnostic services across Australia, supporting hospitals, clinics, and community healthcare settings.
Average Trading Volume: 800,946
Technical Sentiment Signal: Sell
Current Market Cap: A$383.9M
For an in-depth examination of ACL stock, go to TipRanks’ Overview page.